BHATIA PROGRAM
McMaster University
RESEARCH STAFF
DR. ALLISON BOYD
Research Associate
BSc Biology & Psychology
MSc Environmental & Life Sciences
PhD Biochemistry
DANIELLE TARAY-MATHESON
Research Laboratory Technician
HBSc Life Sciences
MSc Pathology & Laboratory Medicine
POST-DOCS
DR. CYRIELLE RICHARD
Post-Doc
BSc & MSc Genetics
PhD Hematology
Cyrielle's project focuses on identifying driver mechanisms involved in the progression of MDS to AML
DR. EKTA MANOCHA
Post-Doc
BSc & MSc Biotechnology
PhD Microbiology
Ekta's project focuses on identifying the role of SUMOylation as a potential target in cancer stem cells
DR. DEANNA PORRAS
Post-Doc
porrasd@mcmaster.ca
BSc & MSc Kinesiology & Health Science
PhD Biochemistry
Deanna's project is focused on reprogramming the differentiation block in human myeloid leukemia
DR. SEAN VANDERSLUIS
HBSc. Biochemistry
Masters Biomedical Technology
PhD Biochemistry
Sean's project focuses on improving personalized medicine approaches in AML & the discovery of cancer stem cell targeting drugs
DR. CAMERON HOLLANDS
Post-Doc
hollancg@mcmaster.ca
HBSc Molecular Biology & Genetics
PhD Biochemistry
Cam's project focuses on characterizing the molecular and cellular kinetics of AML disease relapse post-chemotherapy
DR. ALEXANDER QIAN
BSc. Medical Sciences
Masters Medical Sciences
PhD Medical Sciences
Alex's project aims to elucidate the heterogeneity of leukemia progenitor cells and identify new pathways for targeted therapy
PHD & MASTERS STUDENTS
CHARISA HENLY
Mohammad's project explores the versatile application of high throughput technologies,
aiming to unravel the complex heterogeneity of AML and pinpoint therapeutic candidates.
HBSc Molecular Biology and Genetics
Charisa's project focuses on elucidating the changes in the bone marrow stroma population during pathological conditions such as AML.
AMY QIAO
HBSc Life Sciences
​
Amy's project focuses on using induced pluripotent stem cells to model AML disease processes
MEGHAN STATCHUK
BHSc Biology and Pharmacology
​
Meghan’s project involves utilizing iCas9-mediated CRISPR knockout screening platforms to deconvolute the mechanism of action of candidate drugs that selectively target cancer stem cells.